186 related items for PubMed ID: 36223961
1. Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome.
Liu J, Shen Q, Xie L, Wang J, Li Y, Chen J, Fang X, Tang X, Qian B, Xu H.
BMJ Open; 2022 Oct 12; 12(10):e064216. PubMed ID: 36223961
[Abstract] [Full Text] [Related]
2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K.
BMC Nephrol; 2018 Nov 01; 19(1):302. PubMed ID: 30382824
[Abstract] [Full Text] [Related]
3. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Ravani P, Bonanni A, Ghiggeri GM.
BMJ Open; 2017 Mar 17; 7(3):e013319. PubMed ID: 28314744
[Abstract] [Full Text] [Related]
4. Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial.
Hogan J, Perez A, Sellier-Leclerc AL, Vrillon I, Broux F, Nobili F, Harambat J, Bessenay L, Audard V, Faudeux C, Morin D, Pietrement C, Tellier S, Djeddi D, Eckart P, Lahoche A, Roussey-Kesler G, Ulinski T, Boyer O, Plaisier E, Cloarec S, Jolivot A, Guigonis V, Guilmin-Crepon S, Baudouin V, Dossier C, Deschênes G.
BMJ Open; 2020 Sep 23; 10(9):e037306. PubMed ID: 32967877
[Abstract] [Full Text] [Related]
5. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM.
Cochrane Database Syst Rev; 2020 Apr 16; 4(4):CD002290. PubMed ID: 32297308
[Abstract] [Full Text] [Related]
6. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T.
Clin Exp Nephrol; 2017 Aug 16; 21(4):671-676. PubMed ID: 27558467
[Abstract] [Full Text] [Related]
7. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS, Ha IS, Cheong HI, Kim SY, Lee SJ, Kang HG.
Medicine (Baltimore); 2018 Nov 16; 97(46):e13157. PubMed ID: 30431588
[Abstract] [Full Text] [Related]
8. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
Basu B, Preussler S, Sander A, Mahapatra TKS, Schaefer F.
BMC Nephrol; 2020 Nov 30; 21(1):520. PubMed ID: 33256621
[Abstract] [Full Text] [Related]
9. Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol.
Lugani F, Angeletti A, Ravani P, Vivarelli M, Colucci M, Caridi G, Verrina E, Emma F, Ghiggeri GM.
BMJ Open; 2021 Nov 29; 11(11):e052450. PubMed ID: 34845071
[Abstract] [Full Text] [Related]
10. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ.
Health Technol Assess; 2019 May 29; 23(26):1-108. PubMed ID: 31156083
[Abstract] [Full Text] [Related]
11. Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study).
Ehren R, Benz MR, Doetsch J, Fichtner A, Gellermann J, Haffner D, Höcker B, Hoyer PF, Kästner B, Kemper MJ, Konrad M, Luntz S, Querfeld U, Sander A, Toenshoff B, Weber LT, Gesellschaft für Pädiatrische Nephrologie (GPN).
BMJ Open; 2018 Oct 10; 8(10):e024882. PubMed ID: 30309995
[Abstract] [Full Text] [Related]
12. Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study).
Veltkamp F, Khan DH, Reefman C, Veissi S, van Oers HA, Levtchenko E, Mathôt RAA, Florquin S, van Wijk JAE, Schreuder MF, Haverman L, Bouts AHM.
BMJ Open; 2019 Aug 01; 9(8):e027011. PubMed ID: 31375606
[Abstract] [Full Text] [Related]
13. ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial.
Dirikgil E, van Leeuwen JR, Bredewold OW, Ray A, Jonker JT, Soonawala D, Remmelts HHF, van Dam B, Bos WJ, van Kooten C, Rotmans J, Rabelink T, Teng YKO.
BMJ Open; 2022 Sep 21; 12(9):e061339. PubMed ID: 36130755
[Abstract] [Full Text] [Related]
14. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
Hogan J, Dossier C, Kwon T, Macher MA, Maisin A, Couderc A, Niel O, Baudouin V, Deschênes G.
Pediatr Nephrol; 2019 Feb 21; 34(2):253-259. PubMed ID: 30109447
[Abstract] [Full Text] [Related]
15. Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT.
Christian MT, Webb NJ, Woolley RL, Afentou N, Mehta S, Frew E, Brettell EA, Khan AR, Milford DV, Bockenhauer D, Saleem MA, Hall AS, Koziell A, Maxwell H, Hegde S, Finlay ER, Gilbert RD, Jones C, McKeever K, Cook W, Ives N.
Health Technol Assess; 2022 Jan 21; 26(3):1-94. PubMed ID: 35060851
[Abstract] [Full Text] [Related]
16. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F.
Pediatr Nephrol; 2008 Aug 21; 23(8):1269-79. PubMed ID: 18465150
[Abstract] [Full Text] [Related]
17. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.
Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A, Aoyagi H, Ueno M, Kobayashi N, Uetake K, Nakanishi M, Ariga T.
Pediatr Nephrol; 2019 Jan 21; 34(1):87-96. PubMed ID: 30141179
[Abstract] [Full Text] [Related]
18. REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study.
Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar NCAJ, van den Heuvel LPWJ, Schreuder MF.
BMJ Open; 2017 Sep 27; 7(9):e018148. PubMed ID: 28963315
[Abstract] [Full Text] [Related]
19. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
Pediatr Nephrol; 2017 Nov 27; 32(11):2071-2078. PubMed ID: 28664242
[Abstract] [Full Text] [Related]
20. Crohn's disease following rituximab treatment in a patient with refractory nephrotic syndrome.
Morita K, Shibano T, Maekawa K, Hattori M, Hida N, Nakamura S, Takeshima Y.
CEN Case Rep; 2019 Feb 27; 8(1):55-60. PubMed ID: 30251194
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
